Michael Glatzel

Summary

Country: Germany

Publications

  1. ncbi request reprint High-dose-rate brachytherapy in the treatment of recurrent and residual head and neck cancer
    Michael Glatzel
    Department of Radiotherapy, Zentralklinikum Suhl, Germany
    Laryngoscope 112:1366-71. 2002
  2. ncbi request reprint Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer
    Jens Büntzel
    Department of Otolaryngology, Zentralklinikum Suhl gGmbH, Suhl, Germany
    Semin Radiat Oncol 12:4-13. 2002
  3. ncbi request reprint Tumor markers and lymphatic metastasis in head and neck cancer patients
    Jens Büntzel
    Department of Otolaryngology, Head Neck Surgery, Sudharzkrankenhaus Nordhausen, 99734 Nordhausen, Germany
    Anticancer Res 25:1539-42. 2005
  4. ncbi request reprint Serum selenium in head and neck cancer patients--a new marker of tumor activity?
    Jens Büntzel
    Department of Otolaryngology, Head Neck Surgery, Sudharzkrankenhaus Nordhausen, 99734 Nordhausen, Germany
    Anticancer Res 25:1711-2. 2005
  5. ncbi request reprint Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study
    Jens Buentzel
    Department of Otolaryngology, Head and Neck Surgery, Suedharzkrankenhaus Nodhausen, Nordhausen, Germany
    Int J Radiat Oncol Biol Phys 64:684-91. 2006
  6. ncbi request reprint Zinc concentrations in serum during head and neck cancer progression
    Jens Büntzel
    Department of Otolaryngology, Head and Neck Surgery, Sudharzkrankenhaus Nordhausen, Nordhausen, Germany
    Anticancer Res 27:1941-3. 2007
  7. ncbi request reprint Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study
    Jens Büntzel
    Department of Otolaryngology, Head and Neck Surgery, Sudharzkrankenhaus Nordhausen, Nordhausen, Germany
    Anticancer Res 27:1953-6. 2007

Collaborators

  • Jens Buentzel
  • Jens Büntzel
  • Oliver Micke
  • Frank Bruns
  • Ralph Mücke
  • Dietmar Fröhlich
  • Ulrich Schäfer
  • Klaus Schönekaes
  • Asadulla Garayev
  • Klaus Kisters
  • Klaus G Schönekaes
  • Axel Hornig
  • Klaus Kuttner
  • Ronald Weinaug

Detail Information

Publications7

  1. ncbi request reprint High-dose-rate brachytherapy in the treatment of recurrent and residual head and neck cancer
    Michael Glatzel
    Department of Radiotherapy, Zentralklinikum Suhl, Germany
    Laryngoscope 112:1366-71. 2002
    ..Most reports about brachytherapy in the successful treatment of head and neck tumors used low-dose-rate brachytherapy. There are only a few reports about high-dose-rate brachytherapy (HDRBT) in head and neck cancer patients...
  2. ncbi request reprint Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer
    Jens Büntzel
    Department of Otolaryngology, Zentralklinikum Suhl gGmbH, Suhl, Germany
    Semin Radiat Oncol 12:4-13. 2002
    ..The enhanced therapeutic index may be changed into a prognostic benefit for selected patients with unresectable tumors, if the volume is smaller than 20 cm(3)...
  3. ncbi request reprint Tumor markers and lymphatic metastasis in head and neck cancer patients
    Jens Büntzel
    Department of Otolaryngology, Head Neck Surgery, Sudharzkrankenhaus Nordhausen, 99734 Nordhausen, Germany
    Anticancer Res 25:1539-42. 2005
    ..This study was conducted to evaluate the relationship between the lymph node status and tumor marker status in patients with histologically confirmed head and neck cancer...
  4. ncbi request reprint Serum selenium in head and neck cancer patients--a new marker of tumor activity?
    Jens Büntzel
    Department of Otolaryngology, Head Neck Surgery, Sudharzkrankenhaus Nordhausen, 99734 Nordhausen, Germany
    Anticancer Res 25:1711-2. 2005
    ..The purpose of this work was to investigate the relationship between the tumor volume and the endogenous selenium levels in untreated head and neck cancer patients...
  5. ncbi request reprint Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study
    Jens Buentzel
    Department of Otolaryngology, Head and Neck Surgery, Suedharzkrankenhaus Nodhausen, Nordhausen, Germany
    Int J Radiat Oncol Biol Phys 64:684-91. 2006
    ..This randomized, double-blinded, placebo-controlled, phase III study evaluated the efficacy and safety of i.v. amifostine during radiochemotherapy for head-and-neck cancer...
  6. ncbi request reprint Zinc concentrations in serum during head and neck cancer progression
    Jens Büntzel
    Department of Otolaryngology, Head and Neck Surgery, Sudharzkrankenhaus Nordhausen, Nordhausen, Germany
    Anticancer Res 27:1941-3. 2007
    ..Reduced serum-zinc concentrations are well known as typical laboratory characteristics in advanced head and neck cancer. Our aim was to follow the development of this phenomenon during the disease...
  7. ncbi request reprint Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study
    Jens Büntzel
    Department of Otolaryngology, Head and Neck Surgery, Sudharzkrankenhaus Nordhausen, Nordhausen, Germany
    Anticancer Res 27:1953-6. 2007
    ..The late toxicities due to multimodal therapy of advanced head and neck cancers were analysed. The impact of cytoprotection with amifostine is the specific objective of this report...